Office of Cardiology, Hematology, Endocrinology and Nephrology - Division of Diabetes, Lipid Disorders, and Obesity (DDLO)
The Division of Diabetes, Lipid Disorders, and Obesity (DDLO) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics Licensing Applications (BLAs) for drugs and biologics intended for the prevention, treatment, or diagnosis of conditions including:
- Type 1 and Type 2 diabetes mellitus, including insulins and glucagons
- Weight loss and weight maintenance
- Geriatric frailty and sarcopenia
- Lipodystrophy
- Vasopressins (central diabetes insipidus, noctural enuresis)
- Vitamin deficiency (except vitamin D)
Director: Lisa Yanoff (Acting)
Deputy Director: TBD
Deputy Director for Safety: Anil Rajpal (Acting)
Safety Regulatory Project Manager: Marissa Petrucelli
Associate Director for Labeling: Monika Houston
Associate Director for Therapeutics: Patrick Archdeacon (Acting)
Division Director of Pharm/Tox for Cardiology, Hematology, Endocrinology, and Nephrology: Todd Bourcier (Acting)
Regulatory Operations
Chiefs, Project Management Staff: Julie Van der Waag, Pamela Lucarelli
Contact Us
Mailing Address:
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Diabetes, Lipid Disorders, and Obesity (DDLO)
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-2290
Fax: (301) 595-2123
Resources For You
- Office of Cardiology, Hematology, Endocrinology and Nephrology
- Office of New Drugs
- CDER Offices and Divisions
- Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality